Hear experts' takeaways from ACOG 2025 on menopause care, postpartum depression screening, and obesity management.
Only about 75% of people with a positive result on a stool-based test for colorectal cancer complete screening with a colonoscopy. Fendrick "won't rest" until it's 90%.
Mark Fendrick, MD, thinks that right now, the relative accuracy of blood-based tests for CRC compared with available alternatives is not quite comparable. He explains.
With a population goal of having 80% to 90% of age-eligible Americans screened for colorectal cancer, colonoscopy can not be the initial test for everyone, Fendrick emphasizes.
Never considered the carbon footprint left by a screening for colorectal cancer? Fendrick has and did the research to learn more. He explains in this short video.
ACOG 2025: Laxmi Gannu, MS, discusses key findings from a provider survey on postpartum depression screening practices, training gaps, and referral patterns.
Johanna Finkle, MD, outlines how clinicians can adapt weight management counseling during key stages of a woman’s life, from preconception through menopause.
A panelist discusses how education about anaphylaxis recognition, early epinephrine administration, and addressing barriers like device portability remains crucial, with intranasal epinephrine potentially solving many existing challenges in anaphylaxis management.
A panelist discusses how real-world cases demonstrate both the effectiveness of epinephrine when properly administered and the importance of ensuring patients actually carry their medication, through the stories of a college student with cashew allergy and a child undergoing a peanut challenge.
A panelist discusses how Neffy offers significant advantages over traditional autoinjectors, including longer shelf life (24-30 months), better temperature tolerance, and needle-free administration that addresses several unmet needs in anaphylaxis management.